- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.05. | Pharming GAAP EPS of -$0.02 beats by $0.01, revenue of $79.09M beats by $15.15M | 3 | Seeking Alpha | ||
| 08.05. | Pharming Group N.V. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 08.05. | Pharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business update | 395 | GlobeNewswire (Europe) | First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting... ► Artikel lesen | |
| 30.04. | Pharming Group N.V.: Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director | 1 | GlobeNewswire (USA) | ||
| 30.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 25.04. | Pharming Group N.V.: Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) | 6 | GlobeNewswire (USA) | ||
| 24.04. | H.C. Wainwright maintains Buy rating on Pharming Group stock | 14 | Investing.com | ||
| 24.04. | NICE issues final guidance endorsing Pharming's APDS therapy | 3 | Pharmaceutical Business Review | ||
| 24.04. | Pharming Group N.V.: Pharming Group to report first quarter 2025 financial results on May 8 | 300 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results... ► Artikel lesen | |
| 23.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.04. | Pharming Group N.V.: Pharming receives positive recommendation from NICE for Joenja?(leniolisib) as a treatment for APDS | 320 | GlobeNewswire (Europe) | For media and investors only
Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS
Recommended for adult and pediatric patients 12 years of age and older... ► Artikel lesen | |
| 03.04. | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Q4/24 results/pipeline expansion - Buy | 284 | dpa-AFX | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 03.04.2025 / 17:08 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer... ► Artikel lesen | |
| 03.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.04. | Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers | 5 | SEC Filings | ||
| 03.04. | Pharming Group N.V.: Pharming Group announces the filing of its 2024 Annual Report and Form 20-F | 3 | GlobeNewswire (USA) | ||
| 28.03. | Pharming Group N.V.: Pharming Group to participate in April investor conferences | 270 | GlobeNewswire (Europe) | Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences... ► Artikel lesen | |
| 20.03. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 20.03. | Pharming Group N.V.: Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation | 402 | GlobeNewswire (Europe) | Multi-center clinical trial includes sites located in the US, UK and EU
Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs)
CVID patients demonstrate... ► Artikel lesen | |
| 18.03. | NICE recommends Pharming's Joenja as first treatment for ultra-rare immune disease APDS | 4 | PMLiVE | ||
| 16.03. | Pharming Group NV zeigt Umsatzwachstum und stabilisiert Verluste | 10 | IT BOLTWISE |
Seite:
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 7,148 | -1,00 % | Guggenheim cuts Intellia stock price target to $45, maintains buy | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,940 | -1,28 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
| CENTOGENE | 0,094 | -1,05 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,410 | -2,35 % | ATAI Life Sciences N.V. - 10-Q, Quarterly Report | ||
| BIOMERIEUX | 118,20 | -0,76 % | bioMérieux receives FDA 510(k) Clearance for its VITEK COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance | MARCY L'ÉTOILE, France, March 18, 2025 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration... ► Artikel lesen | |
| CYCLACEL | 2,190 | 0,00 % | Cyclacel Pharmaceuticals GAAP EPS of $0.00 | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,060 | +6,00 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| GENUS | 24,600 | +1,65 % | Genus - Appointment of Financial Adviser & joint Broker | ||
| ABIONYX PHARMA | 1,166 | +0,17 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| ANAPTYSBIO | 17,100 | -6,56 % | AnaptysBio, Inc.: Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update | Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the... ► Artikel lesen | |
| MEIRAGTX | 4,680 | +4,00 % | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease | - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits... ► Artikel lesen | |
| AKESO | 9,050 | -2,69 % | DelveInsight Business Research, LLP: Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market | DelveInsight | The FDA has approved Akeso's PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of recurrent or metastatic non-keratinising nasopharyngeal carcinoma in adults. The approval includes... ► Artikel lesen | |
| MAAT PHARMA | 5,100 | -1,92 % | MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress | Oral presentation will highlight updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.
Poster presentation selected... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,121 | +3,16 % | Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan | Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,03 % bei einem Aktienkurs von 8,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.